A large propensity-matched study found that patients with a documented cannabis use disorder diagnosis had up to 3.7 times the odds of needing postoperative pain medication after hand fracture surgery compared with matched controls. While the findings suggest this population may benefit from individualized perioperative pain planning, the study cannot determine whether cannabis itself causes greater pain or whether other unmeasured factors drive the association.

As cannabis legalization expands and use rates climb, surgeons and perioperative teams increasingly encounter patients with cannabis use disorder in settings where standardized pain protocols were developed without this population in mind. Inadequate perioperative pain control can delay recovery, increase emergency department visits, and erode patient trust. Yet clinicians currently lack evidence-based guidance on how to adjust analgesic regimens for patients with documented CUD. This study provides the most detailed estimate to date of the analgesic gap in a well-defined surgical context, making it directly relevant to clinical workflow decisions.

Closed reduction with percutaneous pinning (CRPP) for hand fractures is among the most common outpatient orthopedic procedures, with relatively predictable pain trajectories that make it a useful model for studying analgesic variation. The investigators identified patients from the TriNetX Global Collaborative Network, a federated database spanning 143 healthcare organizations, and compared those with a pre-existing ICD-10-coded cannabis use disorder diagnosis to those without. Using propensity score matching on demographics, comorbidities, and fracture type, they assembled 546 matched pairs. The mechanistic rationale centers on prior evidence suggesting that chronic cannabinoid exposure may alter pain processing pathways and potentially induce hyperalgesia, though this biological hypothesis remains debated.

In the 30 days following surgery, CUD patients had approximately three times the odds of opioid use (OR 3.00; 95% CI: 2.06 to 4.55), nearly four times the odds of nonopioid analgesic use (OR 3.67; 95% CI: 2.76 to 4.93), and nearly twice the odds of NSAID use (OR 1.83; 95% CI: 1.27 to 2.63). CUD patients also initiated analgesics earlier and used them on more distinct days, suggesting a sustained pattern of elevated analgesic burden rather than a single prescribing event. However, the study measures analgesic prescribing and administration records, not validated pain scores, so it cannot distinguish whether higher medication use reflects genuinely greater pain, provider anticipation of higher needs, or patient-driven requests. The authors appropriately call for prospective studies with standardized pain outcome instruments.

This study does something genuinely useful: it quantifies, in a well-matched cohort, what many of us have observed anecdotally in clinical practice. Patients who use cannabis heavily often seem to have a harder time finding comfort after procedures with standard pain regimens. The threefold increase in opioid use is a striking number. But what the study cannot tell us is whether these patients actually experienced more pain or whether the healthcare system simply responded to a known CUD diagnosis by prescribing differently. That distinction matters enormously. If providers are reflexively escalating opioids because they see a CUD label in the chart, the problem lies with our prescribing culture, not with the patient’s neurobiology.

In my own practice, I approach perioperative planning for cannabis-using patients by first having an honest conversation about their current consumption patterns, including dose, frequency, and form. I set realistic expectations about pain control, often emphasizing multimodal strategies such as scheduled acetaminophen, regional blocks when available, and early physical therapy rather than defaulting to higher opioid doses. The goal is not to withhold relief but to avoid a reflexive opioid escalation that could create new problems while addressing the legitimate reality that these patients may indeed need more attentive pain management.

This study sits at an important but early point in the research arc connecting cannabis use disorder to perioperative outcomes. Prior smaller studies and case series have suggested that cannabis users may require more anesthesia and report higher postoperative pain, but this is among the first to use propensity score matching across a large multi-institutional database to control for the substantial comorbidity burden that typically accompanies CUD. The consistency of the association across three analgesic classes strengthens the signal, though the observational design means residual confounding from unmeasured variables, including polysubstance use severity, mental health burden, and socioeconomic factors, remains a real concern.

From a pharmacological standpoint, clinicians should consider that chronic cannabinoid exposure may alter endocannabinoid tone and potentially modulate opioid receptor sensitivity, though the clinical significance of these mechanisms in humans remains uncertain. The finding that CUD patients used more NSAIDs as well as opioids suggests that the issue is not simply one of opioid tolerance but may reflect a broader alteration in pain processing or reporting. One concrete recommendation: for patients with known CUD presenting for elective hand surgery, a

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care